default author photo

Esther B. Bulle

Department of Intensive Care, University of Amsterdam, Amsterdam UMC

United States

SCHOLARLY PAPERS

1

DOWNLOADS

416

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial

Number of pages: 23 Posted: 30 Jul 2020
University of Amsterdam - Department of Intensive Care, Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Department of Immunology, Maastricht UMC+, Department of Immunology, Maastricht UMC+, Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam - Amsterdam University Medical Centers, Department of Neurology, University of Amsterdam, Amsterdam UMC, Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Rivierenland ziekenhuis - Department of Intensive Care, Clinical Pharmacy, Amsterdam University Medical Centers, Maastricht University - Centre for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Amsterdam - Department of Intensive Care, Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Academic Medical Center, Charité - Universitätsmedizin Berlin - Department of Infectious Diseases and Respiratory Medicine, Metronomia Clinical Research GmbH, InflaRx GmbH, University of Amsterdam - Department of Neurology, nflaRx Pharmaceuticals Inc., Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Maastricht University - Division of Nephrology and Clinical Immunology, InflaRx GmbH and University of Amsterdam - Department of Neurology
Downloads 416 (175,046)

Abstract:

Loading...

COVID-19, complement cascade, randomized controlled trial